European Commission clears proposed acquisition of Genzyme by Sanofi-Aventis
This article was originally published in Scrip
Executive Summary
While the main players are still trying to work out whether a deal that is mutually acceptable to both sets of shareholders can be struck, the European Commission has declared it would not object to the proposed acquisition of Genzyme by Sanofi-Aventis on competition grounds. Consequently, the Commission has granted regulatory clearance under its Merger Regulation for the proposed acquisition.